Posted in | News | Nanomedicine

Cell-Derived Nanoparticles Decrease Infectiousness of SARS-CoV-2

The COVID-19 pandemic highlighted how crucial it is to have treatments ready to prevent viral epidemics, which can otherwise have disastrous effects. There is an immediate need for adaptable platform technologies that could be quickly repurposed to combat viral outbreaks to prepare for the next pandemic or Disease X.

Coronavirus cells or bacteria molecule. Virus Covid-19. Virus isolated on white.

Image Credit: Vector-3D/Shutterstock.com

Under the direction of Assistant Professor Minh Le of the Department of Pharmacology at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and the Institute for Digital Medicine (WisDM), a group of researchers found that nanoparticles called “extracellular vesicles” (EVs) released by cells have the ability to reduce the infectiousness of SARS-CoV-2, including both wild type and variant strains, as well as possibly other infectious diseases.

Our study showed that these cell-derived nanoparticles are effective carriers of drugs that target viral genes precisely. These EVs are therefore an efficient tool for therapeutic intervention in patients who are infected with COVID-19 or other infectious diseases.

Minh Le, Assistant Professor, Institute for Digital Medicine (WisDM) and Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore

The study, which was carried out in collaboration with NUS Medicine’s Biosafety Level 3 (BSL3) Core Facility, the Cancer Science Institute of Singapore at the National University of Singapore, and the School of Physical and Mathematical Sciences at Nanyang Technological University (NTU), revealed potent inhibition of COVID-19 infection in laboratory models utilizing a combination of EV-based inhibition and antisense RNA therapy mediated by antisense oligonucleotides (ASOs).

ASOs are a versatile tool that can be used on any gene of interest. They can recognize and bind to complementary sections of target RNA molecules, causing inhibition and destruction.

The authors used human red blood cell-derived EVs to transport ASOs to critical locations infected with SARS-CoV-2, resulting in an effective reduction of SARS-CoV-2 infection and replication. The researchers also revealed that EVs have particular antiviral capabilities, including the ability to disrupt phosphatidylserine (PS) receptor-mediated viral infection pathways—a crucial pathway used by many viruses to enable viral infection.

These viral inhibitory mechanisms were relevant to many SARS-CoV-2 variations, including the Delta and Omicron strains, ensuring their broad anti-SARS-CoV-2 efficacy.

The study’s findings lead to anti-sense RNA therapy with ASOs as a potentially successful technique for combating future virus outbreaks. The technology created to distribute ASOs via EVs to target the SARS-CoV-2 viral genes can easily be adapted to treat other viral diseases by substituting the ASO sequences with those complementary to the target viral genes.

The study’s first authors, Assistant Professor Le and her graduate students Migara Jay and Gao Chang, are currently designing more potent combinations of ASOs with the use of artificial intelligence prediction models to achieve enhanced viral suppression.

This collaborative endeavor comprises collaboration with the research teams of Associate Professor Edward Chow from WisDM, NUS Medicine, and the BSL3 Core Facility at NUS Medicine.

This remarkable extracellular vesicle-based delivery platform technology coupled with anti-viral therapy is highly promising to combat a broad range of viruses and even Disease X.

Justin Chu, Assistant Professor, National University of Singapore

The latter is a broad term for new and unknown infectious risks such as novel coronaviruses. The word was coined to warn against and stimulate the development of platform technologies, such as vaccinations, medication therapies, and diagnostic tests, that could be quickly customized and deployed in the face of future epidemic and pandemic outbreaks. Assoc Prof Chu is affiliated with NUS Medicine's Infectious Diseases Translational Research Program.

This work brings the scalable and well-tolerated extracellular vesicle-based drug delivery platform an important step closer towards clinical validation studies.

Dean Ho, Provost’s Chair Professor and Director, WisDM, National University of Singapore

Journal Reference:

Jayasinghe, M. K., and Ruan, X. (2023) Red Blood Cell-Derived Extracellular Vesicles Display Endogenous Antiviral Effects and Enhance the Efficacy of Antiviral Oligonucleotide Therapy. ACS Nano. doi:10.1021/acsnano.3c06803

Source: https://nus.edu.sg/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit
Azthena logo

AZoM.com powered by Azthena AI

Your AI Assistant finding answers from trusted AZoM content

Azthena logo with the word Azthena

Your AI Powered Scientific Assistant

Hi, I'm Azthena, you can trust me to find commercial scientific answers from AZoNetwork.com.

A few things you need to know before we start. Please read and accept to continue.

  • Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
  • Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
  • Large Language Models can make mistakes. Consider checking important information.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.